Zhitong Finance App News, Zhonghui Bio-B (02627.HK) announced that the Drug Evaluation Center of the State Drug Administration (China Drug Evaluation Center) approved the new drug clinical trial (IND) application for adsorbed tetanus toxoid vaccine (adsorbed tetanus vaccine) candidate products independently developed by the Group on November 12, 2026.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.